Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617277 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02617277 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 56 participants.
The verdict
NCT02617277, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab). Secondly, the immunogenicity, pharmacodynamics, and preliminary anti-tumour activity will be determined in patients with refractory solid tumours.
Interventions
- DRUG AZD1775
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-12-28 |
| Est. Completion | 2026-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617277
The ClinicalTrials.gov registry entry for NCT02617277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD1775 is the first listed.
NCT02617277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02617277 about?
NCT02617277 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours". This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab). Secondly, the immunogenicity, pharmacodynamics, and preliminary anti-tumour activity will be determined in patients with refractory solid...
What is the current status of trial NCT02617277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-12-28. Estimated completion is 2026-02-17.
What interventions are being tested in trial NCT02617277?
The interventions under investigation include: AZD1775 (DRUG), MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02617277?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.